OmniAb director Foehr sells $29k in shares

OmniAb director/CEO Matthew W. Foehr sold 19,244 shares on April 7, 2026 for ~$28,673 (weighted avg $1.49) while the stock trades at $1.51, down ~18% YTD. OmniAb reported Q4 fiscal 2025 revenue of $8.4M (down from $10.8M prior year) and a net loss of $14.2M, or $0.11/share (vs $0.12/share). Multiple brokers reiterated Buy/Outperform ratings with price targets ranging $4.00–$10.00, reflecting analyst confidence despite the weak quarterly top-line and ongoing losses.

Analysis

OmniAb’s platform is a classic optionality trade: expanding partner counts amplify a long tail of milestone and royalty outcomes while keeping near-term revenue volatile. The second-order winners are not only future royalty streams but service providers and early-stage biotechs that rely on outsourced antibody discovery — sustained partner growth tends to concentrate R&D budgets into a smaller set of best-in-class discovery platforms, increasing switching costs over 12–36 months.

Key risks cluster around capital structure and binary partner readouts. With a small recurring revenue base, the company is likely to need non-dilutive milestones or a financing event within 6–18 months to avoid meaningful dilution; conversely, positive partner trial news can compress time-to-royalty expectations and re-rate the stock sharply. Analysts appear to be anchoring on long-term platform value while underweighting short-term financing and idiosyncratic trial binary risk, creating asymmetric near-term downside versus headline upside.

Positioning should therefore be asymmetric and event-driven: size exposure to capture re-rating from partner milestones while protecting against the more probable path of occasional dilution or trial setbacks. Monitor share-count changes and the cadence of partner announcements as high-value signals — a steady cadence of program additions with clear milestone schedules reduces financing tail risk and materially increases the probability of >=2x outcomes over 12–24 months.

Key Decisions for Investors

• Small speculative long (OABIW equity): Allocate 0.5–1.0% of NAV, time horizon 12–18 months. Set a hard stop at -50% and a staged take-profit at +100% and +200%. Rationale: captures platform re-rate if 1–2 partner milestones progress while limiting blow-up risk from financing or trial failure.
• Long-dated option leverage (OABIW LEAPs): Buy 12–24 month calls sized to 0.25–0.5% of NAV (total premium) to capture asymmetric upside with defined risk. If options liquidity is poor, use low-delta strikes to limit premium; target 3–8x return on positive partner readouts, total loss = premium paid.
• Idiosyncratic pair (long OABIW / short XBI equal-dollar): Size at 1% NAV, hold 6–12 months to isolate platform-specific outcomes from sector moves. Expect relative upside of 150–300% on successful partner news; if the sector rerates broadly, cap losses with a 30% trailing stop on the pair.
• Tactical hedge ahead of known readouts: If a partner trial readout or financing window falls within 3–6 months, buy short-dated puts (or short small equity) representing 0.25% NAV to protect against a binary downside >50%. Cost of the hedge is justified by the high probability of headline-driven volatility in the near term.